Searched for
PHARMACEUTICAL PIPELINE
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...- Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipelineNovo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...
- Japan's Takeda bets on dengue vax to reshape India playbookTakeda Pharmaceutical's new dengue vaccine Qdenga received approval in India. The vaccine is expected to launch commercially in early 2027....
- India, Uzbekistan could explore FTA, says Piyush Goyal; Uzbekistan invites Indian investment in mining, rare earthsIndia and Uzbekistan aim to double bilateral trade to three billion dollars within three years. Businesses are urged to increase investment...
- Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...
- Piramal Pharma to focus on policy, not Trump tariff tweets: Nandini PiramalPiramal Pharma will focus on policy actions amid tariff concerns. Its global manufacturing network offers a significant advantage. The comp...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe next time uncertainty over the firing of missiles in the Gulf region makes you anxious, remember this: It is not the first time that gl...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Cabinet approves Rs 3,030 crore Bhavya Rasayan Scheme for three chemical parksWith a financial commitment of Rs 3,030 crore, the Union Cabinet has approved the Bhavya Rasayan Scheme. This forward-thinking initiative w...
- AstraZeneca 'magic' faces rare test after trial failure, share slideAstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted...
- Cipla expects sequential recovery in North America on new product launches despite tariff uncertaintyCipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAfter four days of relative outperformance, the Indian market is seemingly in trouble: Both the indices (the Nifty and Sensex) and market b...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- After Hormuz, Gate of Tears may make the world cry. What about India?The Bab el-Mandeb Strait, a key shipping route connecting Red Sea and Gulf of Aden, faces growing risks of disruption after Yemen’s Houthi ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsOil is crucial for every part of the Indian economy: From government to consumer, its price impacts spending by every stakeholder. So, till...
- Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bnAlembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug...
- Is Your Leadership Style Too Nice?Many leaders mistake being “nice” for being effective, avoiding hard conversations and decisions in ways that ultimately undermine organiza...
- Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley dealEli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental...
- 101 equity mutual funds doubled money in 5 years; 4 did it in just 3 years. Should you invest now?More than 100 Indian equity mutual funds doubled investors' money over five years, but experts caution against chasing past winners. While ...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
Load More
